NEPHRAMINE 5.4%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEPHRAMINE 5.4% (NEPHRAMINE 5.4%).
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
| Metabolism | Amino acids are metabolized via transamination, deamination, and incorporation into proteins; no specific hepatic or renal enzyme pathway. |
| Excretion | Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible. |
| Half-life | 1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels. |
| Protein binding | Minimal (<10%) for most amino acids; no specific binding proteins. |
| Volume of Distribution | 0.3-0.5 L/kg (distributes primarily into extracellular fluid and lean body mass). |
| Bioavailability | IV: 100% (only route of administration). |
| Onset of Action | IV: Immediate (within minutes) upon infusion start. |
| Duration of Action | Duration limited to infusion period; effects cease shortly after discontinuation (minutes to hours depending on amino acid utilization). |
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
| Dosage form | INJECTABLE |
| Renal impairment | GFR < 50 mL/min: use with caution, reduce total amino acid dose to 0.5-0.8 g/kg/day. GFR < 15 mL/min: avoid use or use only with close monitoring of nitrogen balance. |
| Liver impairment | Child-Pugh class B: reduce dose by 50%. Child-Pugh class C: contraindicated; use specialized hepatic formulas instead. |
| Pediatric use | Weight-based: 1-2 g amino acids/kg/day intravenously; for neonates and infants, initial dose 0.5-1 g/kg/day, titrate up to 2-3 g/kg/day as tolerated. Administer via central line in total parenteral nutrition. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing range (0.6-0.8 g/kg/day) and monitor nitrogen balance and renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NEPHRAMINE 5.4% (NEPHRAMINE 5.4%).
| Breastfeeding | It is not known whether Nephramine 5.4% is excreted in human milk. The M/P ratio has not been determined. Caution is advised when administered to nursing mothers, as amino acid compositions may affect milk protein quality or infant amino acid metabolism. Consider benefits of breastfeeding against potential risks. |
| Teratogenic Risk | Nephramine 5.4% (amino acid injection) is classified as FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, amino acid solutions at high doses have been associated with fetal growth retardation and increased resorptions. Potential risks include metabolic acidosis and hyperammonemia in the fetus, particularly during the second and third trimesters. Use only if clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any component; severe hepatic failure or encephalopathy; inborn errors of amino acid metabolism.
| Precautions | Monitor fluid and electrolyte balance; use with caution in patients with severe liver disease, metabolic acidosis, or hyperammonemia; risk of volume overload in renal impairment. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, blood urea nitrogen (BUN), serum ammonia, acid-base status, and glucose levels regularly. Assess for signs of hyperammonemia, metabolic acidosis, or fluid overload. Fetal monitoring should include ultrasound for growth and well-being, particularly if maternal metabolic disturbances occur. |
| Fertility Effects | No specific studies on fertility effects. High-dose amino acid solutions may alter maternal nitrogen balance and hormone levels, potentially affecting ovulation or implantation. Animal studies have not shown direct impairment of fertility, but clinical data are insufficient. |